```html

Quasi‑malignant Fibrous Histiocytoma (Undifferentiated Pleomorphic Sarcoma)

Overview

Undifferentiated pleomorphic sarcoma (UPS), historically called malignant fibrous histiocytoma (MFH) or “quasi‑malignant” fibrous histiocytoma, is a rare, aggressive soft‑tissue sarcoma that most often arises in the deep fascia or muscle of the extremities, trunk, or retroperitoneum. Because it lacks a specific line of differentiation, pathologists label it “undifferentiated.” The term “quasi‑malignant” is an older descriptor referring to its intermediate‑grade behavior – it is malignant but often slower‑growing than high‑grade sarcomas.<sup>[1][2]</sup>

Who it affects: UPS occurs most frequently in adults between 50 – 70 years of age, with a slight male predominance (≈ 55 % of cases). It is uncommon in children and teenagers, representing less than 5 % of pediatric soft‑tissue sarcomas.<sup>[3]</sup>

Prevalence: Soft‑tissue sarcomas as a whole account for only 1 % of adult cancers. UPS makes up roughly 5‑10 % of all soft‑tissue sarcomas, translating to an incidence of about 1–2 cases per million persons per year in the United States.<sup>[4]</sup> Because the tumor can arise anywhere in the body, its true incidence may be under‑reported.

Symptoms

Symptoms vary by tumor location and size. Most patients notice a painless or minimally painful lump that grows slowly over months. Below is a comprehensive list of possible manifestations:

• Localized mass or swelling – usually firm, non‑fluctuant, and deep to the skin.
• Pain or tenderness – may occur when the tumor presses on nerves, joints, or bone.
• Reduced range of motion – especially when located near a joint (e.g., shoulder, knee).
• Skin changes – overlying skin may become stretched, erythematous, or ulcerated in advanced cases.
• Neurological symptoms – tingling, numbness, or weakness if the tumor compresses peripheral nerves.
• Systemic signs (rare) – fatigue, unexplained weight loss, fever, or night sweats may indicate metastatic disease.
• Respiratory symptoms – when the tumor metastasizes to the lungs, patients may develop cough, shortness of breath, or chest pain.
• Abdominal discomfort – retroperitoneal or intra‑abdominal UPS can cause vague abdominal pain, fullness, or early satiety.

Causes and Risk Factors

The exact cause of UPS is unknown. It is considered a sporadic malignancy, but several factors appear to increase risk:

Genetic and molecular factors

• Complex chromosomal abnormalities – UPS tumors often show multiple copy‑number variations, TP53 mutations, and alterations in the RB1 pathway.
• Prior radiation exposure – therapeutic radiation (e.g., for breast cancer or Hodgkin lymphoma) can induce secondary sarcomas, including UPS, typically after a latency of 5–15 years.<sup>[5]</sup>
• Inherited cancer syndromes – rare conditions such as Li‑Fraumeni syndrome (TP53 mutation) predispose to various sarcomas, including UPS.

Environmental and lifestyle factors

• Chronic lymphedema (Stewart‑Treves syndrome) – long‑standing swelling of an extremity raises sarcoma risk.
• Exposure to certain chemicals (e.g., vinyl chloride, dioxin) – epidemiologic data are limited but suggest a modest increase.
• Immunosuppression – organ‑transplant recipients have a higher incidence of soft‑tissue sarcomas.

Demographic factors

• Age > 50 years (peak incidence).
• Male sex (≈ 55 % of cases).

Diagnosis

Because UPS can mimic benign lumps, a systematic diagnostic work‑up is essential.

Clinical evaluation

• Detailed history (duration, growth rate, pain, prior radiation).
• Physical examination focusing on size, depth, fixation to underlying structures, and skin changes.

Imaging studies

1. Magnetic Resonance Imaging (MRI) – gold standard for soft‑tissue sarcomas; provides precise tumor boundaries, neurovascular involvement, and helps plan surgery.
2. Computed Tomography (CT) – useful for evaluating bone involvement or when MRI is contraindicated; also assesses chest for pulmonary metastases.
3. Positron Emission Tomography (PET‑CT) – detects metabolically active disease and can identify distant metastases.

Biopsy

A core‑needle or incisional biopsy performed by an experienced musculoskeletal oncologist is mandatory before any definitive treatment. Pathology reveals:

• Highly pleomorphic spindle cells with atypical nuclei.
• Storiform (“cartwheel”) pattern in some cases.
• Immunohistochemistry: usually CD68+, vimentin+, desmin‑negative, and lacking specific lineage markers, confirming “undifferentiated.”

Molecular testing (next‑generation sequencing) may identify actionable mutations for targeted therapy, although this is infrequent in UPS.<sup>[6]</sup>

Staging

Staging follows the American Joint Committee on Cancer (AJCC) 8th edition for soft‑tissue sarcoma:

• T – size and depth (e.g., T1 ≤ 5 cm, T2 > 5 cm).
• N – nodal involvement (rare in UPS).
• M – distant metastasis, most commonly lung.

Staging informs treatment planning and prognosis.

Treatment Options

Management is multimodal and should be coordinated by a sarcoma‑specialized multidisciplinary team (surgeon, medical oncologist, radiation oncologist, radiologist, pathologist, and supportive‑care professionals).

Surgery

• Wide local excision with at least 1‑2 cm margins is the cornerstone for localized disease.
• En bloc resection of involved structures (e.g., bone, neurovascular bundles) may be required for complete clearance.
• Limb‑sparing surgery is preferred; amputation is reserved for unresectable or recurrent disease.

Radiation therapy

• Pre‑operative (neoadjuvant) radiation (50 Gy) can shrink the tumor and improve resectability.
• Post‑operative (adjuvant) radiation (60‑66 Gy) is indicated when surgical margins are close or positive.
• Intensity‑modulated radiation therapy (IMRT) or proton therapy may reduce toxicity to nearby organs.

Chemotherapy

The role of systemic chemotherapy is controversial for low‑grade tumors but is standard for high‑grade or metastatic UPS.

• Doxorubicin‑based regimens (e.g., doxorubicin 75 mg/m² q3w) – the most widely studied.
• Ifosfamide combined with doxorubicin for fit patients; higher response rates but increased toxicity.
• Gemcitabine + docetaxel is an alternative for patients unable to tolerate anthracyclines.

Targeted and immunotherapy

• Approximately 15‑20 % of UPS tumors express PD‑L1; checkpoint inhibitors (pembrolizumab, nivolumab) have shown modest activity in early trials.<sup>[7]</sup>
• Molecular profiling may uncover rare actionable alterations (e.g., NTRK fusions) treatable with larotrectinib or entrectinib.

Clinical trials

Enrollment in sarcoma clinical trials (e.g., novel TKIs, CAR‑T cell therapy) should be discussed, as they provide access to cutting‑edge treatments.

Lifestyle and supportive care

• Maintain a balanced diet rich in protein to support wound healing.
• Engage in gentle, physician‑approved physical activity to preserve limb function.
• Smoking cessation and limiting alcohol improve overall treatment tolerance.

Living with Quasi‑malignant Fibrous Histiocytoma (Undifferentiated Pleomorphic Sarcoma)

Survivorship focuses on physical recovery, emotional well‑being, and surveillance for recurrence.

Follow‑up schedule

• First 2 years: clinical exam + MRI of the primary site + chest CT every 3‑4 months.
• Years 3‑5: every 6 months.
• After 5 years: annually if disease‑free.

Managing side effects

• Post‑operative pain – use scheduled acetaminophen/NSAIDs; opioids only as needed.
• Radiation dermatitis – keep the area clean, apply moisturizers, and follow dermatologist advice.
• Chemotherapy‑related fatigue – prioritize rest, short walks, and consider supportive medications like erythropoiesis‑stimulating agents when indicated.
• Lymphedema after extensive surgery – compression garments and manual lymphatic drainage.

Psychosocial support

• Join sarcoma support groups (e.g., Sarcoma Foundation of America).
• Consider counseling or psychiatric care for anxiety/depression.
• Family education ensures caregivers understand wound care, medication schedules, and signs of complications.

Rehabilitation

Physical therapy should begin as soon as the surgeon clears weight‑bearing. Goals include restoring range of motion, strength, and gait, especially after thigh or arm resections.

Returning to work and daily activities

• Discuss with your employer about a phased return; light‑duty work often possible after 4‑6 weeks post‑surgery.
• Avoid heavy lifting (> 10 lb) for at least 3 months unless cleared.
• Use protective padding if the surgical site is superficial.

Prevention

Because most UPS cases are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Avoid unnecessary radiation exposure; discuss risks/benefits of therapeutic radiation with your doctor.
• Protect against chronic lymphedema by managing post‑surgical swelling promptly.
• Adopt a healthy lifestyle—balanced diet, regular exercise, and smoking cessation—to improve overall immune surveillance.
• For individuals with known cancer‑predisposition syndromes, engage in regular genetic counseling and surveillance per specialist recommendations.

Complications

If left untreated or inadequately managed, UPS can lead to serious outcomes:

• Local recurrence – occurs in 20‑40 % of cases, especially when margins are close.
• Metastatic spread – lungs (most common), followed by bone and liver; metastasis reduces 5‑year survival to <30 %.
• Pathologic fracture when the tumor invades bone.
• Neurovascular injury during surgery, causing chronic pain or functional loss.
• Radiation‑induced secondary cancers (rare, but possible decades after treatment).
• Psychological impact – anxiety, depression, and body‑image concerns.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Undifferentiated pleomorphic sarcoma.” Accessed May 2024.
2. World Health Organization. “Classification of Tumours of Soft Tissue and Bone.” 5th ed., 2020.
3. Cleveland Clinic. “Soft Tissue Sarcoma.” 2023.
4. National Cancer Institute. SEER Cancer Statistics Review, 1975‑2022.
5. American Society for Radiation Oncology. “Radiation‑associated sarcoma.” 2022.
6. Journal of Clinical Oncology. “Pathologic and molecular features of undifferentiated pleomorphic sarcoma.” 2021.
7. Nature Medicine. “Immune checkpoint inhibition in soft‑tissue sarcoma: early results.” 2022.

```